Autres langues ABL Texcell Diagnostics

Actions

ABLD

FR001400AHX6

Equipement, fournitures et distribution médicale

Temps réel Euronext Paris 15:51:14 24/09/2026			Varia. 5j.	Varia. 1 janv.
2,300 ^EUR	-4,96%		-10,85%	-23,33%

18/09	Bourse : Solutions 30 et Boiron souffrent, Stellantis pourrait vendre Aramis
18/09	ABL Diagnostics change de nom, mais reste sur le marché réglementé

Autres langues

22/09	ABL Texcell Diagnostics Signs LoI to Acquire Vela's US, Singapore Operations
21/09	ABL Texcell Diagnostics Reaches a New Strategic Milestone With a Proposed Acquisition of Vela Diagnostics' Activities in Singapore and the United States
21/09	ABL Texcell Diagnostics SA signed a letter of intent to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.
18/09	ABL Diagnostics Shareholders Approve Name Change; Euronext Paris Listing to Remain
17/09	ABL Diagnostics Société anonyme has Changed its Name to ABL Texcell Diagnostics
17/09	ABL Diagnostics Becomes ABL Texcell Diagnostics
17/09	ABL Diagnostics Announces Its Participation in Investor Access @ Maison De La Chimie Paris 2026
15/09	ABL Diagnostics to Participate in the European Main MidCap Event Paris 2026 on September 30 and October 1, 2026
14/09	ABL Diagnostics Announces Availability of the Latest All Invest Securities Research Report
11/09	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.
11/09	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings
11/09	ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen
11/09	Abionyx Pharma Partners With ABL Diagnostics Division for Viral Safety Testing of CER-001
10/09	Abionyx Pharma Enters into Strategic Partnership with TEXCELL (Abl Diagnostics) for Viral Safety and Clearance of Biologics
10/09	ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma
08/09	ABL Diagnostics Maintains Revenue Guidance for the Financial Year 2026
08/09	ABL Diagnostics Confirms Its Change of Scale in the First Half of 2026: Revenue up 90.0%, EBITDA Multiplied by More Than Four and Net Income up 343.3% Compared to the First Half of 2025
08/09	ABL Diagnostics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2026
27/08	ABL Diagnostics: Ordinary and Extraordinary General Meeting of September 17, 2026 – Arrangements for the Availability and Consultation of Preparatory Documents
10/08	ABL Diagnostics Plans Listing Transfer to Euronext Growth Paris
07/08	ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris
29/07	ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL
27/07	ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital
23/07	French Court OKs ABL Diagnostics' Industrial Plan to Acquire Texcell
23/07	ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations